Lumera's Q1 Sales Surge 70 Percent as Losses Narrow; Firm Extends ISB Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Lumera yesterday said first-quarter revenues increased 71 percent as R&D spending fell 20 percent and net loss narrowed 15 percent.
 
Total receipts for the three months ended March 31 increased to $860,000 from $503,000 million year over year.
 
Lumera also said it had just over $2 million in backlogged government contracts at the end of the quarter.
 
R&D spending dipped to $1.3 million from $1.6 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.